OR WAIT null SECS
Abzena has launched its AbZelect platforms, designed for improving cell line development.
Abzena announced on Jan. 16, 2023 the launch of AbZelect and AbZelectPRO, its new cell line development (CLD) platforms, designed to speed up the generation of production cell lines for the manufacture of antibodies and recombinant proteins. The platforms are intended to enable the rapid progress of complex biologic drug programs towards clinical trials and investigational new drug (IND) application filing.
According to a company press release, the CLD platforms enable the rapid generation and selection of high-yielding mammalian Chinese hamster ovary cell lines for producing therapeutic proteins and recombinant vaccines. AbZelect was designed for traditional protein programs, such as antibodies. Based on this design, it is optimized across three key areas: vector, host cell line, and process.
AbZelectPRO combines AbZelect with ProteoNic Biosciences’ 2G UNic vector technology, which boosts expression levels and generates higher-producing, stable cell lines that express proteins such as bispecifics, fusion proteins, and other novel modalities, according to the press release. These platforms are expected to shorten timelines from DNA to research cell banks to 15 weeks.
“The higher productivity that’s achievable with the AbZelect and AbZelectPRO platforms means we can produce more drug substances per manufacturing run. These efficiencies will not only expand our capacity and help to reduce the cost of goods for our customers but also reduce the time it takes to get new and critical therapies to patients in need,” said Matthew Stober, CEO, Abzena, in the press release.